NCT05008562

Brief Summary

Critical illness myopathy and neuropathy are associated with prolonged mechanical ventilation, resulting in increased morbidity and mortality in intensive care units, .the investigators aimed to determine the decrease in muscle mass and risk factors that are important causes for the development of myopathy in COVID-19 (+) patients followed in intensive care unit. The study will also evaluate the relationships of patients withthe investigators intensive care-associated muscle weakness (ICU-AW) with other intensive care patient weight scores (SOFA, APACHE II, q SOFA). Sensitivity of anthropometric measurements and ultrasonographic measurements will be compared in the evaluation of sarcopenia. The length of hospital stay, mechanical ventilation time, patient outcomes (mortality/morbidity) information of patients with COVID-19 pneumonia followed in the intensive care unit will be evaluated.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 9, 2021

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 9, 2021

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

June 11, 2021

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 17, 2021

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2021

Completed
Last Updated

December 23, 2022

Status Verified

August 1, 2021

Enrollment Period

Same day

First QC Date

June 11, 2021

Last Update Submit

December 21, 2022

Conditions

Keywords

SarcopeniaICU Acquired WeaknessSARS-CoV-2 Acute Respiratory Disease,

Outcome Measures

Primary Outcomes (7)

  • Effects of COVID-19 ARDS on ICU-AW development, anthropometric measurement,

    The measurements of the patients were recorded as anthropometric ( thigh circumference) on the 1st, 7th, 14th and 21st days. Thigh circumference (centimeter) was measured anthropometrically with a tape measure (centimeter), 15 centimeter above the patella with the leg in extension.

    Change from baseline in thigh circumference at 21 days

  • Effects of COVID-19 ARDS on ICU-AW development, ultrasonographic measurement

    Using an ultrasound imaging device, the thickness of rectus femoris muscles (cm\^2) were measured ultrasonographically (at the same points of anthropometric measurements) with the linear probe.

    Change from baseline in thigh circumference at 21 days

  • Effects of COVID-19 ARDS on ICU-AW development, scoring systems.

    The muscle strength of the patients were evaluated according to the Medical Research Council (MRC) scoring.

    Change from baseline in thigh circumference at 21 days

  • Effects of COVID-19 ARDS on ICU-AW development, scoring systems.

    On the first day of the study, SOFA (Sequential Organ Failure Assessment) score,scoring systems were calculated for each patients.

    Change from baseline at 21 days

  • Effects of COVID-19 ARDS on ICU-AW development, scoring systems.

    On the first day of the study, qSOFA (quick Sequential Organ Failure Assessment) score scoring systems were calculated for each patients.

    Change from baseline at 21 days

  • Effects of COVID-19 ARDS on ICU-AW development, scoring systems.

    On the first day of the study, APACHE-II (Acute Physiology And Chronic Health Evaluation II) scoring systems were calculated for each patients.

    only first day

  • Effects of COVID-19 ARDS on ICU-AW development, nutrition.

    The diet of the patients were standardized by the dietitian.

    21 days

Study Arms (1)

COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT

Patients over the age of 18 who are hospitalized in our intensive care unit with a diagnosis of COVID-19 will be included in the study. The day the patients are admitted to the intensive care unit will be considered the 1st day of the study. SOFA, qSOFA, APACHE II, CRP, procalcitonin values will be recorded on the first day. On the first day of our patients, rectus femoris muscle thickness measurement will be done ultrasonographically (bilateral). In addition, bilateral thigh circumference will be measured anthropometrically (with a tape measure). It is planned to evaluate the muscle strength of the patients according to the MRC (Medical Research Council) scoring. In addition to these measurements, the creatine kinase values in the routine clinical follow-up of the patients, the differences between the fluid intake and output values, inotropic supplements used in their treatment, diuretic needs, and neuromuscular blocker use will also be noted.

Other: COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT

Interventions

there is no interventions to the patients.

COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Being in the Intensive Care Unit * Over the age of 18 * Diagnosed with COVID-19 pneumonia

You may qualify if:

  • Being in the Intensive Care Unit
  • Over the age of 18
  • Diagnosed with COVID-19 pneumonia

You may not qualify if:

  • Under the age of 18
  • Pregnancy
  • Having a cardiac pacemaker
  • Amputated lower limbs Having severe venous insufficiency or major injuries to their lower extremities
  • Having neuromuscular disease
  • Malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gunes Comba Cebeci

Istanbul, Bayrampasa, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
specialist

Study Record Dates

First Submitted

June 11, 2021

First Posted

August 17, 2021

Study Start

June 9, 2021

Primary Completion

June 9, 2021

Study Completion

September 1, 2021

Last Updated

December 23, 2022

Record last verified: 2021-08

Locations